Rogel members present at upcoming AACR meeting
More than 40 Rogel Cancer Center-led research efforts will be presented during the AACR Annual Meeting 2022, which runs April 8-13 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.
You can help amplify the reach and impact of your colleagues’ work by tweeting using #AACR22 and tagging @UMRogelCancer.
Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected]..
ED006 - Development of chemical probes for target validation in hematologic cancers - Jolanta E. Grembecka
4:00 PM – 4:20 PM, New Orleans Theater C
Posters 12:00-1:00 PM
6366 - A novel small molecule inhibitor of MAPK and PI3K ameliorates disease phenotypes in myelofibrosis - Christopher A. Bonham, et al.
5741 - Characterizing isoform switching events in esophageal adenocarcinoma - Yun Zhang, et al.
6049 - Identifying shared features of low-H3K27me3 pediatric brain tumors - Matthew Pun, et al.?
ED028 - Defining the clinical utility of MRD testing: Path to guiding treatment decision making - Daniel F. Hayes
11:00 AM – 11:20 AM, Great Hall BC
ADT12 - Linking glioblastoma purine metabolism and radiation resistance in the laboratory and clinic - Daniel Wahl
1:55 PM – 2:15 PM, Room 243-245
MS.PS01.02 - Molecular Genomics of Cancer Risk and Prognosis - Laura A. Kresty, Chairperson
3:00 PM – 5:00 PM, Room 217-219
PAS03 - Personalized Career Conversations - John M. Carethers, Mentor
5:30 PM – 7:30 PM, Mardi Gras Salon D-E, New Orleans Marriott
Posters 1:30-5:00 PM
21 / 2 - Awareness of HPV and experience with cervical cancer screening in rural Southern Vietnam - Minh Tung Phung, et al.
ADT10 - Peptide Interaction Inhibitors in Cancer Therapeutics - Tomasz Cierpicki, Chairperson
12:30 PM – 2:00 PM, Room 217-219
ADT10 - Predicting druggability of protein-protein interactions to discover new cancer therapeutics - Tomasz Cierpicki
1:25 PM – 1:45 PM, Room 217-219
2176 - NADPH production and redox homeostasis regulate acinar to ductal metaplasia - Megan Radyk
3:05 PM – 3:20 PM, Room 243-245
PAS05 - Navigating the Path to a Successful Career in Cancer Research - John Carethers, Panelist
7:00 PM – 9:00 PM, Acadia Room, New Orleans Marriott
Posters 1:30-5:00 PM
2018 / 22 - Therapeutic benefit of dual ALK and FAK inhibition in neuroblastoma - Seema Chugh, et al.
1700 / 17 - Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications - Andi K. Cani, et al.
SY47 - Minorities in Cancer Research Scientific Symposium: Opportunities to Leverage Legislation and Policies in Addressing Cancer Disparities - John Carethers, Invited Speaker
10:15 AM – 11:45 AM, Room 220-222
SY29 - The application of artificial intelligence in pathology and issues related to deployment, clinical validation, and regulation - Liron Pantanowitz
1:00 PM – 1:20 PM, Room 343-345
3592 - Targeting SWI/SNF ATPases in enhancer-addicted human cancers - Abhijit Parolia
3:20 PM – 3:35 PM, La Nouvelle Orleans C
FO08 - What Is the Causal Link between Race and Early Onset of Colon Cancer? - John Carethers, Moderator and Presenter
5:00 PM – 6:30 PM, New Orleans Theater A
FO08 - Changing epidemiology of CRC: Genetics, geography, and other sociodemographic risk factors - Elena Stoffel
5:10 PM – 5:25 PM, New Orleans Theater A
Posters 9:00 AM-12:30 PM
2792 / 3 - On-chip evaluation of cancer cell-extracellular vesicle interactions using a novel microfluidic microsystem (CellExoChip) Kruthi Srinivasa Raju, et al. (Yoon-Tae Kang presenting)
2697 / 12 - Inhibition of estrogen receptor signaling as a strategy for radiosensitization of ER+ breast cancers - Anna R. Michmerhuizen, et al.
2241 / 23 - Evaluating anal cancer screening approaches in high-risk populations in Puerto Rico - Kandyce G. Keller, et al.
Posters 1:30-5:00 PM
3341 / 19 - Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma - Caitlin M. O’Connor, et al.
3274 / 16 - Targeting NSD family histone methyltransferase activity with irreversible inhibitors - Christina Howard, et al.
3189 / 16 - Characterization of secretory cues that promote brain metastasis using a microfluidic blood brain niche (BBN) device - Christopher Ryan Oliver, et al.
Posters) 9:00 AM-12:30 PM
4012 / 6 - EGFR inhibition in combination with PI3K/AKT/mTOR and/or Bcl-2 inhibition is a promising novel therapeutic approach for inverted sinonasal papillomas and associated sinonasal carcinomas - Athena M. Apfel, et al.
3936 / 10 - Orally bioavailable 'lymphatropic' kinase inhibitors - Brian D. Ross, et al.